SofWave Medical (SOFW) investor relations material

Industry trends and company positioning

• Strong secular tailwinds drive demand for non-invasive skin rejuvenation, with the company leveraging proprietary high-intensity ultrasound technology targeting the mid-dermis for natural collagen, elastin, and hyaluronic acid regeneration.

• Leadership team has a proven track record in building multi-billion dollar companies and executing successful industry consolidations, contributing to de-risked execution and rapid growth.

• The company has achieved significant market share gains, outpacing competitors even during industry downturns, and is supported by a robust patent portfolio and FDA clearances.

Technology and competitive differentiation

• Proprietary technology delivers energy through cooled transducers, ensuring consistent results, minimal downtime, and safety across all skin types, differentiating from competitors like Ulthera and Thermage.

• Device operation is simple and can be delegated, improving clinic efficiency and reducing the need for physician oversight.

• The business model is frictionless, with no inventory or consumable management required, and recurring revenue generated through a pay-per-use pulse system.

Financial performance and business model

• Revenue model combines upfront equipment sales ($115,000 MSRP) with recurring utilization fees ($1.50 per pulse), resulting in over 40% of revenue from high-margin, virtual consumables.

• Gross margin on recurring revenue approaches 100%, with most transactions processed online and on a cash basis, supporting EBITDA profitability above 10% and strong cash flow.

• Top-line growth exceeded 50% last year, with recurring revenue nearing 50% of total revenue.